NRX Pharmaceuticals Inc. (NRXP)
NASDAQ: NRXPHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
NRXP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $125.56M
- EPS (TTM)
- -$0.58
- Dividend yield
- None
- 52-week range
- 1.62 – 5.06
- Day range
- 2.87 – 2.93
- Volume / Avg
- 404.42K / 874.85K
- Beta
- —
- Shares outstanding
- 43.30M
- Next earnings
- Nov 12, 2026
52-week range
NRXP stock today
Shares of NRX Pharmaceuticals (NRXP) finished lower on Oct 7 at $2.90, a drop of 1.36% or $0.04 per share, versus the S&P 500's 0.22% decline. Trading was light, with 404.42K shares changing hands, about 46% of the average daily volume. At this level, NRXP sits in the middle of its 52-week range of $1.62 to $5.06: 42.6% below the high, set on Jun 2, 2026 and 79.0% above the low.
NRXP is up 7.0% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 21.0%. NRX Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.58), so its P/E ratio is not meaningful. NRX Pharmaceuticals's next earnings report is expected on Nov 12, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About NRX Pharmaceuticals
Company profileNRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jonathan C. Javitt M.D., M.P.H.
- Headquarters
- Wilmington, DE
- Employees
- 29
- IPO year
- 2017
- Website
- nrxpharma.com
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$38.50+1227.59%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 12, 2026
NRX Pharmaceuticals peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SPRBSpruce Biosciences Inc. | 44.40 | +3.77% | $127.61M | vs NRXP |
| HURATuHURA Biosciences Inc. | 1.98 | +1.54% | $126.18M | vs NRXP |
| TNXPTonix Pharmaceuticals Holding Corp. | 7.55 | -1.88% | $129.49M | vs NRXP |
| FHTXFoghorn Therapeutics Inc. | 2.09 | +6.09% | $124.12M | vs NRXP |
| CBUSCibus Inc. Class A | 1.62 | +3.18% | $123.81M | vs NRXP |
| HUMAHumacyte Inc. | 0.4723 | -1.19% | $131.20M | vs NRXP |
| VTVTvTv Therapeutics Inc. Class A | 31.01 | +3.26% | $122.61M | vs NRXP |
| SEERSeer Inc. Class A | 2.21 | +0.91% | $122.37M | vs NRXP |
Indexes, lists and sector
Appears in lists
NRX Pharmaceuticals stock FAQ
What is NRX Pharmaceuticals's stock price today?
NRXP last traded at $2.90 as of Oct 7, 4:00 PM EDT, down 1.36% on the day. Prices are delayed at least 15 minutes.
Does NRX Pharmaceuticals pay a dividend?
No. NRX Pharmaceuticals does not currently pay a regular cash dividend.
When is NRX Pharmaceuticals's next earnings date?
NRX Pharmaceuticals is expected to report earnings on Thursday, November 12, 2026.
Who is NRX Pharmaceuticals's CEO?
Dr. Jonathan C. Javitt M.D., M.P.H. is the chief executive officer of NRX Pharmaceuticals Inc., which has about 29 employees.
Has NRXP ever split its stock?
Yes. The most recent NRXP stock split was a 1-for-10 split on Apr 2, 2024.
What is the NRXP 52-week high?
The 52-week high for NRXP is $5.06 and the 52-week low is $1.62. The stock is currently 42.6% below its high.